Frequently asked questions
The global mitotane drug market was valued at USD 17.5 Million in 2022.
The mitotane drug market is expected to grow at a CAGR of 4.8% between 2023 and 2030, reaching USD 25.46 Million in 2030.
Oral tablets/capsules are the leading segment by formulation, holding over 65% share in value in 2022.
The adrenal cortical carcinoma (ACC) segment governs the global demand for mitotane drugs, holding a massive share of over 54% in 2022.
The advanced or metastatic disease segment will post the highest CAGR over the projection period.
With more than one-third of the market in 2022, North America is driving the expansion of the mitotane drug industry.
The top players include HRA Pharma Rare Diseases, Bristol-Myers Squibb Company, TherDose Pharma Pvt. Ltd, Hikma Pharmaceuticals, Tizig Pharma Pvt. Ltd, Aspen Pharmacare, Prime Therapeutics, Novartis Pharmaceuticals Corporation, and Others.
The major market drivers of the mitotane drug industry include the increasing incidence of adrenocortical carcinoma (ACC) and the orphan drug status with regulatory support.
The major market restraints of the mitotane drug industry encompass its limited indications and niche market, as well as the significant side effects and tolerability challenges associated with mitotane treatment.
The major market opportunities of the mitotane drug industry lie in exploring combination therapies to enhance treatment efficacy and leveraging orphan drug exclusivity for potential market expansion into new indications.